Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis

The basic aim of the study was to develop and evaluate the triple drug loaded cationic nano-vesicles (cNVs), where miltefosine was used as a replacement of surfactant (apart from its anti-leishmanial role), in addition to meglumine antimoniate (MAM) and imiquimod (Imq), as a combination therapy for the topical treatment of cutaneous leishmaniasis (CL). The optimized formulation was nano-sized (86.2 +/- 2.7 nm) with high entrapment efficiency (63.8 +/- 2.1% (MAM) and 81.4 +/- 2.3% (Imq)). In-vivo skin irritation assay showed reduced irritation potential and a decrease in the cytotoxicity of cNVs as compared to conventional NVs (having sodium deoxycholate as a surfactant). A synergistic interaction between drugs was observed against intracellular amastigotes, whereas the in-vivo antileishmanial study presented a significant reduction in the parasitic burden. The results suggested the potential of surfactant free, triple drug loaded cNVs as an efficient vehicle for the safe topical treatment of CL. (c) 2021 Elsevier Inc. All rights reserved.

Automated summary

This study aimed to develop and evaluate triple drug loaded cationic nano-vesicles (cNVs) for the topical treatment of cutaneous leishmaniasis (CL). The optimized formulation of cNVs showed high entrapment efficiency and reduced irritation potential, demonstrating its potential as an efficient and safe vehicle for the treatment of CL.